October 16, 2020 -- via Seeking Alpha -- By: Manshi Mamtora, CFA, SA News Editor

- PAO Group (OTCPK:PAOG +10.5%) anticipates entering into an agreement with a contract research organization or CRO within the next two weeks.

- The CRO engagement will be a major breakthrough in advancing PAOG's RespRx treatment for Chronic Obstructive Pulmonary Disease (or COPD) toward FDA approval.

- PAOG acquired RespRx from Kali-Extracts (OTCPK:KALY -8.3%), which is a cannabis treatment under development for COPD derived from a patented cannabis extraction method.

- Related: PURA in management takeover deal with PAO Group.

Press Release

Other stocks on the move: AITX, OZSC, and NGCG

Source: https://seekingalpha.com/news/3622545-paog-to-soon-finalize-cro-engagement-for-cannabis-drug